Boothbay Fund Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Boothbay Fund Management’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28,513	Closed	-$914K	–	2890
2022 Q1	$914K	Sell	28,513 -38,773	-58%	-$1.11M	0.02%	953
2021 Q4	$1.46M	Buy	67,286 +9,514	+16%	+$210K	0.03%	597
2021 Q3	$1.27M	Sell	57,772 -6,930	-11%	-$139K	0.04%	651
2021 Q2	$1.26M	Buy	64,702 +11,335	+21%	+$206K	0.04%	584
2021 Q1	$920K	Buy	53,367 +14,801	+38%	+$234K	0.03%	638
2020 Q4	$618K	Buy	38,566 +565	+1%	+$7.85K	0.02%	670
2020 Q3	$405K	Buy	+38,001	New	+$453K	0.02%	720
2019 Q4	–	Sell	-3,034	Closed	-$47K	–	1058
2019 Q3	$47K	Hold	3,034	–	–	﹤0.01%	725
2019 Q2	$68K	Hold	3,034	–	–	0.01%	677
2019 Q1	$208K	Hold	3,034	–	–	0.02%	603
2018 Q4	$160K	Buy	3,034 +278	+10%	+$17.8K	0.02%	511
2018 Q3	$187K	Hold	2,756	–	–	0.02%	665
2018 Q2	$326K	Sell	2,756 -711	-21%	-$71.3K	0.03%	451
2018 Q1	$287K	Buy	+3,467	New	+$393K	0.03%	489

Other funds holding SRRA

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Boothbay Fund Management's SRRA Position: Q2 2022 in Review

Boothbay Fund Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 28,513 shares — an estimated $914K sold.

Boothbay Fund Management first reported a position in SRRA in Q1 2018 and held it in 14 quarters. The position peaked at $1.46M in Q4 2021. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

Boothbay Fund Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Boothbay Fund Management sold 28,513 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $914K.
Boothbay Fund Management first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 14 quarters.
Boothbay Fund Management's Sierra Oncology, Inc. Common Stock position peaked at $1.46M in Q4 2021.
109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.